Angiomyolipoma (AML) is a mesenchymal neoplasm caused by insufficient or defective activation of the TSC1 or TSC2 genes, which leads to uncontrolled activation of the mammalian target of rapamycin (mTOR) pathway [15]. The gene discussed is MTOR; the disease is angiomyolipoma.